These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9419454)

  • 21. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
    Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
    Drexler HG; MacLeod RA; Uphoff CC
    Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
    Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Exp Hematol; 2000 Mar; 28(3):276-82. PubMed ID: 10720692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expansion in vitro and cytotoxicity of dendritic cells from patients with chronic myeloid leukemia.
    Ji L; Xing PN; Wei XC; Wang T; Li MS; Zhang WG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr; 13(2):198-204. PubMed ID: 15854276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
    Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
    Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro.
    Sondel PM; Hank JA; Wendel T; Flynn B; Bozdech MJ
    J Clin Invest; 1983 Jun; 71(6):1779-86. PubMed ID: 6223050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An in vitro dendritic cells-induced T lymphocytes cytotoxicity study activated by thaw frozen K562 lysates antigen in chronic myeloid leukemia].
    Zuo XL; Zhou X; Liu XH; Chen F; He L; Meng J; Qu XJ
    Zhonghua Nei Ke Za Zhi; 2006 Dec; 45(12):1013-6. PubMed ID: 17327003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
    He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
    Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
    Spencer A; Granter N
    Exp Hematol; 1999 Sep; 27(9):1397-401. PubMed ID: 10480430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
    Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
    Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro T-cell receptor V beta repertoire analysis may identify which T-cell V beta families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation.
    Epperson DE; Margolis DA; McOlash L; Janczak T; Barrett AJ
    Br J Haematol; 2001 Jul; 114(1):57-62. PubMed ID: 11472345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients.
    Fujii S; Fujimoto K; Shimizu K; Ezaki T; Kawano F; Takatsuki K; Kawakita M; Matsuno K
    Cancer Res; 1999 May; 59(9):2150-8. PubMed ID: 10232602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
    Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
    Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation.
    Dermime S; Mavroudis D; Jiang YZ; Hensel N; Molldrem J; Barrett AJ
    Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells.
    Dietz AB; Bulur PA; Erickson MR; Wettstein PJ; Litzow MR; Wyatt WA; Dewald GW; Tefferi A; Pankratz VS; Vuk-Pavlović S
    J Hematother Stem Cell Res; 2000 Feb; 9(1):95-101. PubMed ID: 10738977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.